EFB Dengue Literature Review

Age-Associated B Cell

6 min read

Age-Associated B Cell

This page is the canonical entry for the age-associated B cell (ABC) named population specifically. For the field-level synonymy map across “atypical,” “ABC,” “T-bet⁺,” “CD11c⁺,” “DN,” and “alternative lineage” labels — and how they route to precise sub-populations — see the umbrella Atypical B Cell. For the human IgD⁻CD27⁻ effector that the IgD⁻CD27⁻ ABC subset maps onto, see DN2 B Cell.

Overview

Age-associated B cells (ABCs; also “T-bet⁺ B cells,” “age/autoimmunity-associated B cells”) were first defined in aged mice as CD19⁺CD21⁻CD23⁻ B cells expressing the transcription factor T-bet and the integrin CD11c (Hao 2011). They are rare in the young and accumulate with age; they also expand prematurely in autoimmunity and chronic infection. “ABC” is, in current usage, primarily a murine term, with the human “DN2” subset regarded as its closest counterpart — but the equation is only partial (see Contradictions).

ABC is a heterogeneous superset, not a single cell. Per Tangye (2023) the ABC population comprises CD27⁺ B cells, IgD⁺ B cells, and — predominantly — IgD⁻CD27⁻ (DN) cells. Only this IgD⁻CD27⁻ fraction corresponds to DN2; the CD27⁺ and IgD⁺ members fall outside the DN definition. This is the central distinction that separates the ABC label from the DN label (see Lamprinou2026 - ABCs and DN B Cells).

Key Points from Literature

  • Phenotype and aging. ABCs are CD19⁺CD21⁻CD23⁻T-bet⁺CD11c⁺, rare in young healthy individuals and steadily increasing with age; a subset shows reduced BCR-mediated antibody production consistent with immunosenescence while retaining other functions (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Hao 2011 / Cancro 2020).
  • Differentiation programme. ABCs are hyper-responsive to endosomal TLR7 and TLR9 and differentiate under TLR stimulation combined with IFN-γ and/or IL-21: IL-21 robustly induces CD11c; IFN-γ primarily promotes T-bet. BCR signalling contributes (with TLR/IFN-γ/IL-21/CD40) but is insufficient alone (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Cancro 2020 / Liu 2024 / Naradikian 2016 / Rubtsov 2017 / Imabayashi 2025). TLR7 is X-linked — a proposed partial basis for the female autoimmunity bias.
  • Heterogeneous isotype/marker composition. Most ABCs are class-switched (IgG or IgA), but the population also contains unswitched IgD⁺ cells by scRNA-seq, and some ABCs express the memory marker CD27 (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Ambegaonkar 2022 / Rubtsov 2011 / Tangye 2023).
  • IgD⁺ ABCs are not naive. They carry somatic hypermutation and are clonally related to IgD⁻ cells, indicating prior antigen experience (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Maul 2021; see Somatic Hypermutation).
  • Transcriptomics (murine). ABCs are discrete from B1 and follicular B cells; they highly express CD11c and T-bet with Ig-heavy-chain and CD138 transcripts and intermediate plasma-cell-differentiation TFs, interpreted as probable plasma-cell precursors; IL-21-inducible and cell-adhesion genes are upregulated in autoimmunity (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Rubtsov 2011 / Wang 2018).
  • Effector functions beyond antibody. Pro-inflammatory cytokine/chemokine production, antigen presentation with strong phagocytic capacity, and T-cell activation (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Xie 2025).
  • Origin debated. A GC-experienced origin is proposed for at least a subset (diverse Ig repertoire, SHM, antigen-driven activation), but homeostatic proliferation and GC-independent/extrafollicular routes are not excluded (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Cancro 2020). This contrasts with DN cells, which are more strongly tied to extrafollicular differentiation.
  • Disease associations. Premature expansion in SLE, RA, Sjögren’s, SSc, and MS — in some cases correlating with disease activity, autoantibody titres, and organ involvement (e.g., T-bet⁺ B cells track SLE activity and lupus nephritis as a candidate biomarker); also induced by chronic HIV, hepatitis C, and malaria (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Sachinidis 2020/2025 / Kourkouni 2024 / SoRelle 2025 / Portugal 2017 / Knox 2017).
  • Therapeutic targeting. BAFF inhibition (belimumab) and CD20 depletion (rituximab) reduce ABC frequencies in SLE blood; a broader portfolio includes IRF5 inhibitors, JAK inhibitors (baricitinib), adenosine A2a agonists, TNF inhibitors, tocilizumab (anti-IL-6R), and ROCK inhibitors (fasudil) (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Sachinidis 2024/2025 / Ramsköld 2019).
  • Cross-reference — transcriptomic correlate. The “alternative lineage” defined by scRNA-seq/CITE-seq (atBC1–3 + MBC1; T-bet/CD11c/FCRL5⁺) is the high-dimensional transcriptomic correlate of the ABC/atypical cluster, present at ~20% of B cells even in non-exposed donors, with CD11c the best single surface marker (see Sutton2021 - Alternative Lineage B Cells in Vaccination and Infection, n=4 CITE-seq).
  • Cross-reference — nomenclature caution. The “ABC”/“atypical” label conflates ≥5 populations and its identity/function depend on context; precise DN nomenclature is preferred (see Sanz2025 - Human Atypical B Cells Overview, review).

Contradictions & Debates

  • ABC ≈ DN2 phenotypically, but ≠ DN2 transcriptomically. Even where ABCs and DN2 share the T-bet⁺CD11c⁺ phenotype, comparative transcriptomics show ABCs are distinct from other CD11c⁺ subsets including DN2, with elevated cytokine/chemokine expression not seen in the others (see Lamprinou2026 - ABCs and DN B Cells, opinion, citing Maul 2021). The wiki’s working “ABC ≈ DN2” equivalence is therefore a phenotypic approximation limited to the IgD⁻CD27⁻ ABC subset, not a transcriptomic identity.
  • Murine vs human depletion sensitivity. Murine ABCs resist anti-BLyS and anti-CD20 depletion in lupus models (Knox 2025), whereas human SLE ABCs are sensitive to the same interventions (Ramsköld 2018; Faustini 2022) — and rituximab resolves DN expansion in SLE (see Anolik2004 - Rituximab and B Cell Abnormalities in SLE). Whether this is a species difference or a context/disease-stage difference is unresolved (see Lamprinou2026 - ABCs and DN B Cells, opinion).
  • Origin unresolved: GC-experienced vs homeostatic proliferation vs extrafollicular — likely a mix that varies by context.
  • Framework provenance. Much of the ABC↔DN synthesis (and the four-subset DN taxonomy it relies on) is self-referential to the Sachinidis/Garyfallos group; cross-lab validation is incomplete — the same caveat the wiki applies to the Sanz lab’s DN classification (see Sanz2025 - Human Atypical B Cells Overview).

Atypical B Cell, DN2 B Cell, Double-Negative B Cell, DN3 B Cell, T-bet, CD11c, CD27, IgD, TLR7, IL-21, CD20, Germinal Center, Extrafollicular Response, Somatic Hypermutation

Sources

Graph View

Backlinks